Life Science Washington Institute is one of only 13 accelerators in the nation to partner with BARDA’s DRIVe program to solve challenging problems spanning modern health security threats and daily medical care.

What is BARDA? 
The Biomedical Advanced Research and Development Authority (BARDA) is part of the Assistant Secretary for Preparedness and Response within the US Department of Health and Human Services. Since it was established in 2006, BARDA has facilitated 42 FDA approvals, licenses, and clearances for products addressing health security threats. BARDA’s mission is accomplished through public-private partnerships with industry to share risk, improve efficiency, and accelerate development while sustaining a marketplace that guarantees continued access to the vaccines, therapeutics, diagnostics, and other meidcal products vital to health security.

What is DRIVe and the DRIVe Accelerator Network? 
The Division of Research, Innovation, and Ventures (DRIVe) was established by BARDA with the goal of building a portfolio of products representing disruptive and innovative approaches to transforming health security. The DRIVe Accelerator Network was launched in 2018 to partner with investment and innovator communities across the nation to stimulate innovation through both non-dilutive and dilutive funding sources. Life Science Washington Institute is one of thirteen accelerators participating in this national network. DRIVe focuses on two main impact areas: Early Notification to Act, Control, and Treat (ENACT) and Solving Sepsis.

DRIVe Areas of Interest:

  • Early Notification to Act, Control, and Treat (ENACT) 
    • ENACT’s focus areas are on-person, wearable, and biosensing devices (host response and direct pathogen detection); host-based diagnostic devices; indirect indicators and artificial intelligence for prediction; and biomarker discovery and panel validation.  
  • Solving Sepsis
    • The focus areas for Solving Sepsis are advanced research and development of sepsis diagnostics and devices, post-sepsis monitoring, pediatric devices, and implementation science technologies.  
  • Other Areas 
    • DRIVe will seek a limited number of additional extremely bold, radical, and disruptive innovative solutions that will have the ability to transform health security. These include – but are not limited to – creating universal treatment options for broad classes of pathogens, ensuring access to life-saving medical countermeasures, and transforming medical countermeasure development by eradicating animal testing.

For information on applying for one of the DRIVe funding opportunities, visit https://drive.hhs.gov/partner.html 

 

Contact Laura Sconyers laura@lswinstitute.org with any questions or for more information!